BioNTech's Clinical Pipeline Takes Center Stage at European Oncology Conference

BioNTech presents strong lung cancer trial data for Gotistobart & Pumitamig as it focuses its pipeline, despite financial pressures and a major leadership transition.

New clinical data presented by BioNTech SE at the concluding sessions of the European Lung Cancer Congress 2026 in Copenhagen has provided a robust update on several key oncology candidates. For a company navigating a significant strategic shift, these late-stage trial signals are particularly consequential.

Financial Context and Strategic Focus

The promising clinical readouts arrive during a period of substantial corporate transformation for the Mainz-based biotech. Co-founders Ugur Sahin and Özlem Türeci are set to transition to a new, independent mRNA innovation venture by the end of 2026. BioNTech will retain a minority stake, sharpening its own strategic emphasis on commercializing its late-stage pipeline.

The company's financial landscape presents a dual narrative. Revenue guidance for 2026 stands at €2.0 to €2.3 billion, a figure that continues to reflect the decline in demand for COVID-19 vaccines. Concurrently, adjusted research and development expenditures are projected to rise to between €2.2 and €2.5 billion. This planned investment means BioNTech is channeling more capital into R&D than it currently generates in sales.

This backdrop is mirrored in the company's equity performance. Shares are trading near a 52-week low and remain well below key moving averages, a valuation that underscores market skepticism regarding the ongoing transition. The stock's potential for re-rating later this year is widely seen as dependent on the strength of upcoming pivotal trial results.

Detailed Clinical Data Highlights

The most compelling data point came from the CTLA-4 antibody Gotistobart, which is being developed in collaboration with OncoC4. In a non-pivotal segment of the PRESERVE-003 trial for squamous non-small cell lung cancer (NSCLC), the therapy demonstrated a 54% reduction in the risk of death compared to standard chemotherapy. This effect was observed in second- or third-line treatment settings, where patient options are historically limited. The pivotal phase of this study is already underway.

BioNTech also presented updated findings for Pumitamig, a bispecific PD-L1xVEGF-A immunomodulator. The results covered applications in both small cell and non-small cell lung cancer. The company is currently supporting two global Phase 3 trials—ROSETTA Lung-01 and Lung-02—aimed at further validating this candidate.

Furthermore, early-stage data for the HER3-targeting antibody-drug conjugate BNT326/YL202 was disclosed publicly for the first time. This included initial combination data with Pumitamig.

Looking ahead, BioNTech's operational goal is to have 15 active Phase 3 studies in oncology by the end of the calendar year, underscoring the scale of its clinical ambitions beyond its pandemic-era work.